BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's key products are LibiGel® (testosterone gel) in Phase III clinical development under an SPA, to treat female sexual dysfunction, and Elestrin™ (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding $2.0 - $4.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.
The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery systems and aesthetic medicine (BioLook™).
